Statistics

Total Visits

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)82

Select a period of time:

Number of views in the range

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)41

Views

Views
May 20254
June 20259
July 202521
August 20250
September 20250
October 20252
November 20255
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States13
Brazil10
Turkey3
Colombia2
United Kingdom2
South Africa2
Argentina2
Barbados1
Canada1
Chile1
 

Top cities views

Views
Istanbul2
Abington1
Alvorada do Norte1
Ananindeua1
Angers1
Ankara1
Belo Horizonte1
Cleveland1
Clovis1
Compton1